Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

364
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
364
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

649
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
649
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

923
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
923
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.3K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.3K
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

1.0K
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Catalase Specifically Binds Antipsychotic Clozapine: Experimental and In Silico Insights into Interactions, Complex Stability, and Dose-Dependent Enzyme Activity Modulation.

Molecules (Basel, Switzerland)·2026
Same author

Discrimination of Bipolar Disorder and Schizophrenia Patients Based on LC-HRMS Lipidomics.

Metabolites·2026
Same author

Job Demands and Resources as Predictors of Burnout Dimensions in Special Education Teachers.

European journal of investigation in health, psychology and education·2025
Same author

Antioxidant Supplementation with ProCloSupp Protects Against Renal Toxicity of Atypical Antipsychotics in Rats: Implications for Safer Treatment Strategies.

Life (Basel, Switzerland)·2025
Same author

Zooplankton mortality and distribution around a seismic survey.

Scientific reports·2025
Same author

Plasma and Serum LC-MS Lipidomic Fingerprints of Bipolar Disorder and Schizophrenia.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Mar 15, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K

Improving Current Treatments for Schizophrenia.

Nadja P Maric1,2, Milica J Jovicic2, Marina Mihaljevic2

  • 1School of Medicine, University of Belgrade, Belgrade, Serbia.

Drug Development Research
|September 17, 2016
PubMed
Summary
This summary is machine-generated.

Current schizophrenia treatments primarily target dopamine receptors, but novel drugs are exploring other pathways to address cognitive and negative symptoms. Developing targeted therapies for schizophrenia is crucial for improved patient outcomes.

Keywords:
NMDRantipsychoticclinical trialdopaminedrug discovery

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.8K

Related Experiment Videos

Last Updated: Mar 15, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.8K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Schizophrenia treatment has evolved from crude methods to dopamine receptor antagonists.
  • Current antipsychotics, while effective, show limited superiority across generations, with clozapine as a notable exception.
  • Dopamine receptor blockade is essential but insufficient for a complete antipsychotic response.

Purpose of the Study:

  • To review the current status of investigational drugs for schizophrenia.
  • To highlight novel therapeutic strategies beyond dopamine receptor blockade.
  • To emphasize the need for treatments addressing cognitive and negative symptoms, and psychosis risk.

Main Methods:

  • Literature review of preclinical and clinical research on schizophrenia therapeutics.
  • Analysis of drugs targeting various neurotransmitter systems (glutamate, glycine, etc.).
  • Examination of novel approaches including intracellular signaling and genetic targets.

Main Results:

  • Existing antipsychotics primarily target dopamine receptors.
  • Emerging therapies investigate glutamate, glycine, and other pathways.
  • Improvements are seen with drugs acting on non-dopaminergic targets and genetic factors.

Conclusions:

  • Novel drug development for schizophrenia should target cognitive and negative symptoms.
  • Addressing endophenotypes and deconstructing the concept of schizophrenia is key.
  • Developing diverse therapeutic strategies is essential for better patient outcomes.